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ABSTRACT
Objectives: To perform a systematic review of
reported HRs of all cause dementia, Alzheimer’s
disease (AD) and vascular dementia (VaD) for late-
life depression and depressive symptomatology
on specific screening instruments at specific
thresholds.
Design: Meta-analysis with meta-regression.
Setting and participants: PubMed, PsycInfo, and
Cochrane databases were searched through 28
February 2014. Articles reporting HRs for incident
all-cause dementia, AD and VaD based on published
clinical criteria using validated measures of clinical
depression or symptomatology from prospective
studies of general population of adults were selected
by consensus among multiple reviewers. Studies that
did not use clinical dementia diagnoses or validated
instruments for the assessment of depression were
excluded. Data were extracted by two reviewers
and reviewed by two other independent reviewers.
The most specific analyses possible using
continuous symptomatology ratings and categorical
measures of clinical depression focusing on single
instruments with defined reported cut-offs were
conducted.
Primary outcome measures: HRs for all-cause
dementia, AD, and VaD were computed where possible
for continuous depression scores, or for major
depression assessed with single or comparable
validated instruments.
Results: Searches yielded 121 301 articles, of which
36 (0.03%) were eligible. Included studies provided a
combined sample size of 66 532 individuals including
6593 cases of dementia, 2797 cases of AD and 585
cases of VaD. The increased risk associated with
depression did not significantly differ by type of
dementia and ranged from 83% to 104% for
diagnostic thresholds consistent with major
depression. Risk associated with continuous
depression symptomatology measures were consistent
with those for clinical thresholds.
Conclusions: Late-life depression is consistently and
similarly associated with a twofold increased risk of
dementia. The precise risk estimates produced in this
study for specific instruments at specified thresholds
will assist evidence-based medicine and inform policy
on this important population health issue.
INTRODUCTION
In a clinical environment where no cure for
Alzheimer’s disease (AD) and other demen-
tias is available or likely to be developed in
the near future, and in the context of a
growing ageing population it is increasingly
important to consider the potential of pre-
ventative approaches to decrease the impact
of these debilitating conditions.1 2 This
requires the identiﬁcation of risk factors and
estimation of the magnitude of their effect,
but critically it also requires the availability of
reliable measures of risk exposure based on
speciﬁc, validated instruments so individuals
at higher risk can be identiﬁed and interven-
tions and/or treatment can be calibrated at
the individual level. Moreover, evidence-
based medicine requires that clinical advice
and decision-making be informed by precise
and reliable evidence based on validated
Strengths and limitations of this study
▪ This study used a robust methodology that
included a very broad search of the literature
using clearly defined search terms and stringent
inclusion and exclusion criteria.
▪ Particular care was taken to assess study
characteristics so only studies that used compat-
ible exposure and outcome measures would be
combined.
▪ Detailed subanalyses were conducted to provide
estimates for specific tools at specific
thresholds.
▪ Study quality, publication bias and influence of
relevant factors were formally investigated by
meta-regression.
▪ The study was limited by the relatively small
number of articles with relevant data published
in this domain and, particularly so for vascular
dementia, and by the fact that the Centre for
Epidemiological Studies Depression scale (CES-
D) was the only instrument that could be ana-
lysed separately.
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instruments at known thresholds.3 Unfortunately, this
evidence is not available.
A link between late-life depression and dementia has
already been established and population-level risk esti-
mates are available. However, results from studies investi-
gating this question have important limitations.4–6 Of
three available meta-analyses on this topic, none has
reported on risk measures related to speciﬁc instru-
ments. Current evidence has been produced by combin-
ing ﬁndings based on different instruments and using
both continuous measures of depressive symptomatology
and categorical classiﬁcation of major or minor depres-
sion with all three systematic reviews including ﬁndings
based on self-report.4–6 In addition, some of the avail-
able meta-analyses combined ﬁndings from studies using
outcome measures of dementia based on accepted diag-
nostic criteria (eg, Diagnostic and Statistical Manual
(DSM), National Institute of Neurological and
Communicative Disorders and Stroke and the
Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA)) with those of studies using criteria
of unclear validity or relating to Mild Cognitive
Impairment (MCI) and not dementia.4 In at least one
instance ﬁndings unrelated to dementia (cognitive
decline in non-demented participants) were included in
the analyses.4 These methodological limitations have
likely led to less reliable estimates of risk which are not
clearly attributable to single screening instruments with
known clinically relevant cut-offs.
The aim of this study was therefore to systematically
review the literature on dementia risk for late-life depres-
sion and conduct meta-analyses pooling separately com-
patible ﬁndings from population studies using either
continuous measures or speciﬁed cut-offs on validated
instruments (eg, Centre for Epidemiological Studies
Depression scale (CES-D)) to assess depression status and
only in those studies which relied on widely accepted clin-
ical criteria for dementia (eg, DSM-IV). Other aims
included estimating and reporting relative risks (RRs) for
dementia subtypes including AD and vascular dementia.
METHODS
This systematic review and meta-analysis follow the
Meta-analysis of Observational Studies in Epidemiology
(MOOSE) and the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)
guidelines.7 8
Search strategy
We conducted a systematic literature search of PubMed,
PsycInfo and Cochrane databases for studies describing
the association between depression (deﬁned by self-
reported scales or clinical diagnoses) and dementia inci-
dence published between 1996 through 28 February
2014. Details of search terms are presented in online
supplementary table ST1. In summary, we combined two
sets of search terms which identiﬁed articles relating to
(1) depression, anxiety (because of its comorbidity with
depression), or medication for these conditions AND
(2) measures of cognition or diagnosis of any type of
dementia. Searches were restricted to human studies
and articles published in English. In addition, we
searched the reference lists of identiﬁed relevant publi-
cations and reviews. Searches were conducted by experi-
enced and qualiﬁed researchers following our published
methodology.9–11 All articles were reviewed for inclusion
by two reviewers ( JY and SK). An independent review of
all articles was conducted by a second set of reviewers
(KJA and NC). Any disagreement was resolved by con-
sensus among all reviewers.
Selection criteria and article screening
The study inclusion criteria ensured that all articles
included in the review met the Oxford Centre for
Evidence-Based Medicine Level of Evidence 1B (http://
www.cebm.net). Studies included following article
screening were required to be prospective, longitudinal,
population-based studies with a minimum follow-up
period of 1 year. Studies were required to measure
depression at baseline or during a follow-up period that
preceded the ﬁnal follow-up examination. Baseline
depression was required to be measured using a standar-
dised assessment tool with articles relying on self-report
of depression diagnosis excluded from the analysis. The
outcome measure had to include dementia. Studies
were required to have screened for dementia at baseline
unless the sample mean age at baseline plus two SDs was
less than 60 years old. Cross-sectional, experimental and
clinical studies and studies with a sample size of less
than 100 and those not reporting on original published
peer-reviewed studies were excluded to ensure only
research of high quality would be considered. We identi-
ﬁed articles eligible for further review by performing an
initial screen of titles and abstracts, followed by a full-text
review.
Data extraction
Data relating to depression and dementia diagnosis were
extracted by two reviewers ( JY and SK) from included
articles for potential meta-analysis. Information
extracted included: study design (sample source,
number of participants and observation period), sample
characteristics (country, percentage female, average age,
age range, years of education, dropout rate), measure-
ment of depression (measurement scale used and/or
clinical criteria), covariates included in statistical
models, dementia assessment and clinical criteria, and
unadjusted and/or adjusted estimates of associations.
Where results for more than one follow-up period were
reported for the same study, the estimate from the
longest follow-up was selected. Adjusted results were
used where available. Data extraction was checked by a
third reviewer (NC). Where insufﬁcient data were avail-
able in articles meeting the inclusion criteria authors
were contacted directly.
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Statistical analysis
We used HRs as common measure of association across
studies and considered RRs as equivalent since it has
been shown that for rare events they can be considered
equivalent.12 We assessed heterogeneity across studies
with the Q statistic (with p<0.10 being suggestive of sig-
niﬁcant heterogeneity) and the I2 statistic (values of
25%, 50% and 75% were indicative of low, medium and
high heterogeneity). The HRs were pooled using the
DerSimonian-Laird random-effects model13 as the
ﬁxed-effects model is regarded as inappropriate in this
type of meta-analysis where study design and method-
ology vary substantially.14 Sensitivity analyses were con-
ducted to identify studies that excessively contributed to
heterogeneity with the leave-one-out method. The pos-
sible presence of publication bias was assessed through
visual inspection of funnel plots, with the ‘trim and ﬁll’
method,15 and with the ‘fail-safe’ method.16 In addition,
sensitivity analyses were conducted to evaluate the inﬂu-
ence of selected study and participants characteristics on
results. Analyses were conducted in R V.3.117 using the
metafor package V.1.9.318 and Review Manager V.5.1.19
Data synthesis
Data were pooled separately across studies for continuous
and categorical measures of depression predicting all-
cause dementia, AD or vascular dementia (VaD). Least
speciﬁc analyses including studies using more diverse
measures of depression were conducted ﬁrst, followed by
more speciﬁc analyses which focused on single instru-
ments and/or on single cut-offs. Studies were considered
compatible for combined analyses if (1) they provided
risk estimates for the same type of measure (categorical
or continuous) (2) they reported on instruments and
cut-offs that would be widely considered as similar and
comparable (eg, the long and the short form of the
CES-D which have been validated against each other or
instruments at speciﬁc thresholds validated against clin-
ical criteria) (3) they estimated the risk for the same type
of dementia (all-cause, AD or VAD) (4) they did not
report on the same cohort. For continuous depression
measures, data from all compatible studies were pooled
in a ﬁrst step followed by analyses including only instru-
ments used to assess depressive symptomatology with a
similar range (eg, CES-D range 0–60 and Hamilton rating
scale for depression (HAM-D) 0–54). For categorical
depression measures, data from all compatible studies
using validated cut-offs (eg, CES-D≥20) or clinical diag-
noses based on accepted criteria (eg, DSM-IV) were
pooled in a ﬁrst step. In studies which used the CES-D
and reported on multiple cut-offs, estimates for a cut-off
of 20/21 were used as this threshold has been reported as
optimum for screening for major depression20 (Note,
however, that Fuhrer et al21 have used a threshold of 17
for men and 23 for women because French validation
studies have found these cut-offs most sensitive for clin-
ical depression in their population and therefore we have
considered them compatible but also conducted
sensitivity analyses without this study). This was followed
by analyses based on single instruments at a speciﬁc
cut-off. Studies which exclusively reported an outcome of
AD and/or VaD were not pooled in all-cause dementia
analyses. Studies using the short form of CES-D with a
cut-off of 10 were pooled with those using the long form
with a cut-off of 16 as the psychometric properties of
these two forms have been found to be comparable.22
Studies were evaluated for methodological quality using
the Newcastle-Ottawa scale.23 Inﬂuence of study
characteristics on pooled estimates, including study
quality, proportion of females, length of follow-up, and
sample mean age, was investigated by meta-regression.
RESULTS
Literature search
The search strategy identiﬁed 121 301 unique citations.
After initial screening based on titles and abstracts 700
publications remained for further assessment. After
close inspection of these articles and application of
inclusion and exclusion criteria a further 565 articles
were excluded (ﬁgure 1). Of those, 99 publications did
not report relevant data or necessary data could not be
extracted or obtained from authors, leaving 36 publica-
tions reporting on 29 unique cohorts for meta-analysis.
Among included articles two were obtained from refer-
ence lists.
Of the 36 articles included 28 studies reported results
on all-cause dementia, 28 studies on AD, 10 studies on
VaD and surveyed a total of 66 532 participant including
6593 participants with all-cause dementia, 2797 with AD,
and 585 with VaD. Regions of origin of participants
included Europe (n=19), North America (n=13 studies),
South Korea (n=2) and China (n=1). We considered the
results as adequately adjusted if they were adjusted for at
least age and education, but where available, we
included the more fully adjusted models in analyses.
Most studies adjusted for age, sex and education (n=21).
Multiple reports
Findings based on the same cohort were reported mul-
tiple times for six studies covered by 14 separate articles.
When multiple reports were available for the same
cohort, a risk estimate from only one publication was
used in any single analysis. The most appropriate esti-
mates were selected based on recency, sample size and
methodology. When different articles from the same
cohort reported on different depression measures (eg,
continuous vs categorical, different cut-off, different
diagnostic tools) or on different diagnostic outcomes
(dementia, AD and VaD) estimates from the same
cohort were sometimes used in different analyses (but
never in combination).
Study characteristics
Characteristics of the 36 selected studies are presented in
table 1. The assessment of depression was most frequently
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based on: CES-D (n=17), Geriatric Mental State (GMS)
(n=4), Geriatric Depression Scale (GDS) (n=3), HAM-D
(n=2), Comprehensive Psychopathological Rating Scale
(CPRS) (n=1), Neo (n=1), Symptom Checklist (SCL)-90
(n=1), clinical diagnosis (DSM-III/IV, n=5; Composite
International Diagnostic Interview (CIDI), n=1), or inter-
national classiﬁcation of diseases (ICD)-9 (n=1).
Dementia diagnosis was most frequently established
based on DSM-III/IV criteria (n=22), GSM-AGECAT
(n=2), ICD9/10 (n=2) or Cambridge Cognition
Examination (CAMGOG) (n=1). AD diagnosis was most
frequently established based on National Institute of
Neurological and Communicative Disorders and Stroke
and the Alzheimer's Disease and Related Disorders
Association (NINCDS-ADRDA) (n=22) or DSM-III/IV
(n=3) criteria. VaD diagnosis was based on National
Institute of Neurological Disorders and Stroke and
Association Internationale pour la Recherche et
l'Enseignement en Neurosciences (NINDS-AIREN)
(n=8) or DSM-III/IV (n=2) criteria.
Study quality rating
Most studies were of excellent quality as attested by the
scores ranging from 7 to 9 on the Newcastle-Ottawa
scale (maximum 9; see online supplementary table
ST2). Five of 36 studies were rated as not representative
of the population mostly because they only reported on
one gender. Eleven studies did not control for at least
age and sex together, while only four studies did not
control for other factors. Five studies did not fully
account for all participants.
Summary risk estimates
Summary HRs for different measures of depression
(continuous measures of symptomatology or categorical
clinical thresholds), and different dementia outcome
categories (all-cause dementia, AD and VaD) are pre-
sented in table 2. Sufﬁcient data were only available for
the CES-D using a cut-off of either 20 or 16 to conduct
subanalyses on individual scales at speciﬁed thresholds.
More detailed statistical outputs for all analyses are pre-
sented in online appendix SA1.
Depression and all-cause dementia risk
Risk estimates were ﬁrst pooled across 10 studies24–32
which assessed depression symptomatology as a continu-
ous measure and a diagnosis of all-cause dementia as
outcome. Instruments used to assess depression
Figure 1 Flowchart of the search and study selection process. AD, Alzheimer’s disease; VaD, vascular dementia.
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Table 1 Characteristics of included studies (n=36).
Author, year
(number of
participants)
Country
(ethnic origin)
Follow-up
years
(SD)
Age
years
(SD)
Female
(%)
Education,
years (SD)/
level
Drop-out
rate (%)
Baseline
cognition
score (SD)
Depression
measure
(cut-off)
Baseline
depression
score (SD)
Dementia diagnosis
and criteria
(number of cases)
Barnes et al,
2012
(n=13535)
USA
(24.2%
non-white)
6.0 (NR) 81.1 (4.5) 57.9 85.6% with
high-school or
higher
55.46% NR ICD-9 NR Dementia (ICD9,
n=3046)
AD (ICD9, n=749)
VaD (ICD9, n=314)
Becker et al,
2009 (n=288)
USA
(17.4%
non-white)
7.1 (NR) 77.5 (3.7) 63.2 61.5% with
high-school or
higher
34.7% NR CES-D-SF
(≥10)
NR AD (NINCD-ADRDA,
n=48)
Blasko et al,
2010 (n=284)
Austria* 2.5 (NR) 78.3 (0.5) ∼56.5 10.6 years
(2.2)
14.8% 28.1 (1.4)
MMSE
GDS
(continuous)
1.6 (1.6) AD (NINCDS-ADRDA,
n=33)
Chen et al,
1999 (n=803)
USA (3%
non-white)
4.5 (NR) 73.7 (5.0) 60.0 61.4% with
high-school or
higher
15.8% 24 (NR)
MMSE
mCES-D
(continuous)
NR Dementia (DSM-III-R,
n=78)
AD (NINCDS-ADRDA,
n=64)
Chen et al,
2008 (n=1329)
China (NR) 1.0 (NR) >65 (NR) NR NR 27.8% NR GMS-AGECAT NR Dementia (GMS-
AGECAT, n=75)
Chen et al.,
2008 (n=2157)
UK (NR) 4.0 (NR) >65 (NR) NR NR 58.7% NR GMS-AGECAT NR Dementia (GMS-
AGECAT, n=176)
Dal Forno et al,
2005 (n=1357)
USA† (NR) 6.1 (NR) 65.5
(12.0)
42.4 16.8 (2.7) NR NR CES-D
(continuous,
≥20, ≥16)
7.1 (6.8) Dementia (DSM-III-R,
n=125)
AD (NINCDS-ADRDA,
n=107)
Devanand
et al, 1996
(n=478)
USA‡ (70%
non-white)
2.54
(1.12)
∼72 (NR) ∼70 10.4 (4.8) 41.6% NR HAM
(continuous)
4.8 (4.8) Dementia (DSM-III-R,
n=61)
AD (NINCDS-ADRDA,
n=57)
Dotson et al,
2010 (n=1113)
USA† (10.5%
non-white)
23.6 (NR) 52.7
(18.8)
42.3 16.6 (2.8) NR NR CES-D (≥16) NR Dementia (DSM-III-R,
n=142)
AD (NINCDS-ADRDA,
n=96)
Fuhrer et al,
2003 (n=3777)
France (NR) 8.0 (NR) 75.2 (6.9) 58.3 62.9% with
primary
school
certificate or
higher
37.4 25.6 (3.7)
MMSE
CES-D (≥23
females, ≥17
males)
10.2 (9.3) Dementia
(DSM-III-TR, n=280)
AD (NINCDS-ADRDA,
n=200)
VaD (n=37)
Gatz et al,
2005 (n=766)
Canada§
(NR)
5 (NR) 74.5 (6.0) 61.7 10.4 (3.2) 35.4 NR CES-D
(continuous,
≥13, ≥16, ≥17,
≥21)
6.1 (7.0) Dementia (DSM-III-R,
n=56)
AD (NINCDS-ADRDA,
n=36)
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Table 1 Continued
Author, year
(number of
participants)
Country
(ethnic origin)
Follow-up
years
(SD)
Age
years
(SD)
Female
(%)
Education,
years (SD)/
level
Drop-out
rate (%)
Baseline
cognition
score (SD)
Depression
measure
(cut-off)
Baseline
depression
score (SD)
Dementia diagnosis
and criteria
(number of cases)
Geerlings et al,
2008 (n=486)
Netherlands
(NR)
5.9 (1.6) 73.5
(∼7.5)
49.0 2.9 (1.6) on
8-point scale
(from no
primary to
tertiary)
NR 27.7 (2.1)
MMSE
CES-D (≥16) NR Dementia (CAMDEX,
n=44)
AD (NINCDS-ADRDS,
n=33)
Geerlings et al,
2000 (n=1911)
Netherlands¶
(NR)
3.2 (NR) 73.1 (5.5) 62.3 8.6 (2.6) 39.3% NR GMS-AGECAT NR AD (DSM-IV, n=53)
Goveas et al,
2011 (n=6376)
USA (13%
non-white)
5.4 (1.6) 70.1 (3.8) 100 92.8 with high
school or
higher
14.7% NR CES-D–SF (≥5) NR Dementia (DSM-IV,
n=102)
Heser et al,
2013 (n=2663)
Germany**
(NR)
6 (NR) 81.3 (3.4) 65.3 39.0% with
high school or
higher
11.2% NR DSM-IV,
GDS-15 (≥6)
NR Dementia (DSM-IV/
ICD10, n=308)
AD (DSM-IV, n=152)
VaD (NINDS-AIREN,
n=56)
Heun et al,
2006 (n=615)
Germany (NR) 4.7 (1.2) 68.1 (8.2) 59.83 NR 18.8% NR CIDI/DSM-IIIR NR AD (DSM-IIIR, n=38)
Irie et al, 2008
(n=1932)
USA (100%
Japanese
American)
6.1 (NR) 76.3 (3.6) 0 96.8% with
more than
6 years of
education
21.6% NR CES-D (11-item
version; ≥9)
NR Dementia (DSM-III-R,
n=98)
AD (NINCDS-ADRDA,
n=NR)
VaD (California AD
Diagnostic and
Treatment Centres
criteria, n=NR)
Jessen et al,
2010 (n=2415)
Germany**
(NR)
3 (NR) 79.5 (3.6) 64.3 34.1% with
high school or
higher
25.5% 45.5 (3.2)
SISCO
GDS (≥6) 2.1 (2.2) Dementia (DSM-IV,
n=110)
AD
((NINCDS-ADRDA,
n=54)
VaD (NINDS-AIREN,
n=26)
Jessen et al,
2011 (n=1526)
Germany**
(NR)
3.81 (NR) 80.1 (3.6) 65.7 36.0% with
high school or
higher
38.0% NR GDS (≥6) NR AD (NINCDS-ADRDA,
n=88)
Jungwirth et al,
2009 (n=487)
Austria* (NR) 5 (NR) 75.8 (0.5) 60.9 98% with
secondary
school or
higher
16.8% NR DSM-IV NR AD (NINCDS-ADRDA,
n=30)
VaD (NINDS-AIREN)
Continued
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Table 1 Continued
Author, year
(number of
participants)
Country
(ethnic origin)
Follow-up
years
(SD)
Age
years
(SD)
Female
(%)
Education,
years (SD)/
level
Drop-out
rate (%)
Baseline
cognition
score (SD)
Depression
measure
(cut-off)
Baseline
depression
score (SD)
Dementia diagnosis
and criteria
(number of cases)
Kim et al, 2010
(n=518)
South Korea††
(NR)
2.4 (0.3) 71.8 (5.1) 54.4 NR 17.1% NR GDS (Korean
version, ≥14)
NR Dementia (DSM-IV,
n=45)
AD (NINCDS-ADRDA,
n=34)
VaD (NINDS-AIREN,
n=7)
Kim et al, 2011
(n=518)
South Korea††
(NR)
2.4 (0.3) 71.8 (5.1) 54.4 NR 17% NR Geriatric Mental
State schedule
(GMS)
NR Dementia (DSM-IV,
n=45)
AD (NINCDS-ADRDA,
n=34)
VaD (NINDS-AIREN,
n=7)
Kohler et al,
2011 (n=771)
Netherlands
(NR)
9 (NR) 67.2 (7.3) 48.0 49.5% with
high school or
higher
11.3% 27.8 (1.8)
MMSE
SCL-90 (top
quartile,
continuous
20.9 (6.2) Dementia (DSM-III-R
and IV, n=37)
AD (NINCDS-ADRDA,
n=26)
VaD (NINDS-AIREN,
n=11)
Lenoir et al,
2011 (n=7989)
France‡‡ (NR) 4 (NR) 74.0 (5.4) 61.3 23.8% with
high
education
level
22.3% 27.4 (1.9)
MMSE
CES-D (f>22,
m>16)
NR Dementia (DSM-IV,
n=276)
AD (NINCDS-ADRDA,
n=180)
VaD (NINDS-AIREN,
n=24)
Li et al, 2011
(n=3410)
USA (NR) 7.1 (NR) 74.9 (6.2) 59.9 63.8% with
college
degree
8.1% 93.1 (5.0)
CASI
CES-D-11 (≥11) 4.2 (4.4) Dementia (DSM- IV,
n=658)
AD (NINCDS-ADRDA,
n=386)
VaD (NINDS-AIREN,
n=89)
Luchsinger
et al, 2008
(n=526)
USA‡ (79.5%
non-white)
5.1 (3.3) 75.1 (6.4) 67.7 8.6 (4.4) NR NR HAM
(continuous,
≥10)
4.6 (4.4) AD (NINCDS-ADRDA,
n=114)
Luppa et al,
2013 (n=888)
Germany (NR) 4.3 (2.4) 81.3 (4.5) 73.4 64.3% with
low education
29.8% 27.1 (1.9)
MMSE
DSM-III-R
CES-D
(continuous,
≥23)
NR Dementia (DSM-III-R/
IV, n=183)
Palmer et al,
2007 (n=185)
Sweden (NR) 3.4 (0.6) 84 (5.1) 84.9 39.2% with
high school
education or
higher
22.4% NR CPRS NR AD (NINCDs-ADRDA,
n=10)
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Table 1 Continued
Author, year
(number of
participants)
Country
(ethnic origin)
Follow-up
years
(SD)
Age
years
(SD)
Female
(%)
Education,
years (SD)/
level
Drop-out
rate (%)
Baseline
cognition
score (SD)
Depression
measure
(cut-off)
Baseline
depression
score (SD)
Dementia diagnosis
and criteria
(number of cases)
Palsson et al,
1999 (n=267)
Sweden (NR) 3 (NR) 85 (NR) ∼70.8 NR 46.4% 27.9 (2.3)
MMSE
DSM-III-R NR Dementia (DSM-III-R,
n=50)
Saczynski et al,
2010 (n=949)
USA (NR) 8 (NR) 79.3 (5.0) 63.6 96.4% with
high school or
higher
NR NR CES-D
(continuous,
≥16)
7.4 (7.5) Dementia (DSM-IV,
n=164)
AD (NINCDS-ADRDA,
n=136)
Samieri et al,
2008 (n=1214)
France‡‡ (NR) 4 (NR) 74.3 (4.9) 61.5 40.1% with
high school or
higher
10.9% NR CES-D (f>22,
m>16)
7.4 (7.5) Dementia (DSM-IV,
n=65)
Schmand et al,
1997 (n=2114)
Netherlands¶
(NR)
4 (NR) 74.3 (5.4) 62.9 NR 41.1% 28.1 (1.5)
MMSE
GMS-AGECAT 1.6 (1.1) Dementia (GMS-
AGECAT, n=131)
St John et al,
2002 (n=998)
Canada§ (NR) 5 (NR) 75.3 (NR) 60.2 9.9 (NR) 32.6% 89.5 (NR)
3MS
CES-D (≥16) NR Dementia (DSM-III-R,
n=93)
van der
Kommer et al,
2010 (n=521)
Sweden (NR) 8 (NR) 83.3 (3.0) 67.4% 29.4% with
elementary
school or
more
47.4% NR CES-D (≥16) NR Dementia (DSM-III-R,
n=93)
Vilalta-Franch
et al, 2012
(n=451)
Spain (NR) 5 (NR) 76.9 (5.5) 65.4 4.3 (3.8) 5.09% NR CAMDEX,
DSM-IV
NR Dementia (DSM-IV,
n=52)
AD (DSM-IV, n=30)
VaD (DSM-IV, n=14)
Wilson et al,
2003 (n=130)
USA (NR) 3.9 (NR) 81.0 (6.6) 52.3 18.1 (3.6) <5% NR CES-D-SF
(continuous)
NR AD (NINCDS-ADRDA,
n=51)
Wilson et al,
2011 (n=785)
USA (NR) 3.4 (1.4) 80.7 (7.4) 76.3 14.5 (3.1) 4.3% 28 (2.1)
MMSE
NEO personality
inventory
revised
(continuous)
11 (4.9) AD (NINCDS-ADRD,
n=94)
Studies reporting on the same cohort: *Vienna Transdanube Ageing study (VITA), †Baltimore Longitudinal Study of Aging (BLSA); ‡Washington Heights and Inwood, Columbia Aging Project,
§Manitoba Study of Health and Aging (MSHA), ¶Amsterdam Study of the Elderly (AMSTEL), **Study on Aging, cognition and dementia, ††Korean prospective community survey of late-life
psychiatric morbidity ‡‡Three-City Study (3C).
AD, Alzheimer’s disease; CAMDEX, Cambridge Mental Disorders of the Elderly Examination; CASI, Child & Adolescent Symptom Inventory; CES-D, Centre for Epidemiological Studies
Depression scale; CIDI, Composite International Diagnostic Interview; CPRS, Comprehensive Psychopathological Rating Scale; DSM, Diagnostic and Statistical Manual; GDS, Geriatric
Depression Scale; GMS, Geriatric Mental State; GMS-AGECAT , Geriatric Mental State - Automated Geriatric Examination for Computer Assisted Taxonomy; HAM, Hamilton rating scale for
depression; ICD, International classification of diseases; mCES-D, modified Center for Epidemiologic Studies Depression scale; MMSE, Mini-Mental State Examination; NINCDS-ADRDA,
National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association; NINDS-AIREN, National Institute of Neurological
Disorders and Stroke and Association Internationale pour la Recherche et l'Enseignement en Neurosciences; NR, not reported; SCL, Symptom Checklist; VaD, vascular dementia.
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included the CES-D, HAM, GSM, and the SCL-90. In a
second analysis estimates were only pooled across
studies using instruments of similar range. This
included the CES-D and HAM. The two sets of analyses
led essentially to identical results indicating that each
one point increase on the CES-D/HAM in a pooled
sample with a mean age of 73.2 years (SD∼6) was asso-
ciated with a 5% increased risk of dementia over a
mean follow-up of 5.2 years (n=8644) (see table 2 and
ﬁgure 2). In addition, because the study by Devanand
et al was the only study reporting results as RR, we con-
ducted additional analyses excluding this study to
determine whether this difference substantially inﬂu-
enced outcomes. These analyses showed that results
remained identical when all continuous measures were
considered (HR 1.05, 95% CI 1.02 to 1.08) and margin-
ally different for CES-D/HAM measures (HR 1.04, 95%
CI 1.02 to 1.07).
With respect to categorical thresholds HRs were
pooled across 11 studies21 25 27 28 30 33–36 and, as
expected, risk estimates were higher for more stringent
clinical criteria. A clinical diagnosis or a score greater
than 20/21 on the CES-D (or equivalent) in individuals
(n=15 553) in a pooled sample with a mean age of
Table 2 Summary of risk estimates (HRs) for different measures of depression (continuous measures of symptomatology or
categorical clinical thresholds), and different dementia outcome categories (all-cause dementia, Alzheimer’s disease, vascular
dementia)
Depression assessment
Dem AD
HRs (n) HR 95% CI I2, % HRs (n) HR 95% CI I2, %
Clinical thresholds
All 11 1.98 1.50 to 2.63 38.34 10 2.04 1.40 to 2.98 60.28
CES-D>20 5 1.83 0.95 to 3.52 71.85 5 1.97 0.96 to 4.04 70.96
CES-D>16 9 1.69 1.46 to 1.97 0.00 6 1.58 1.25 to 2.00 0.00
Continuous measures
All 10 1.05 1.02 to 1.08 63.06 10 1.06 1.02 to 1.10 62.06
CES-D/HAM 8 1.05 1.02 to 1.07 54.82 6 1.06 1.00 to 1.12 72.87
CES-D, Centre for Epidemiological Studies Depression scale; HAM, Hamilton rating scale for depression.
Figure 2 Forest plots of
analyses investigating the risk of
dementia (top row) and
Alzheimer’s disease (bottom row)
associated with continuous (left
column) and categorical (right
column) depression measures
including all comparable
instruments.
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72.0 years (SD∼6) was associated with an 83% increased
risk of dementia over a mean follow-up of 8.2 years.
Sensitivity analyses without the study by Fuhrer et al
which used the equivalent validated French thresholds
yielded a HR of 2.18 (95% CI 1.28 to 3.71). When a
cut-off of 1618 27 31 33 34 37–40 on the CES-D was used a
69% increased risk was observed.
Depression and AD risk
Risk estimates were ﬁrst pooled across 10
studies24 25 27 29 31 41–44 which assessed depression symp-
tomatology as a continuous measure and a diagnosis of
AD as outcome. Instruments used to assess depression
included the CES-D, HAM, GDS, SCL-90 and the NEO.
In a second analysis estimates were only pooled across
studies using instruments of similar range. This included
the CES-D and HAM.24–27 29–31 The two sets of analyses
led essentially to identical results indicating that each
one point increase in a pooled sample with a mean age
of 72.7 years (SD∼6) on the CES-D/HAM was associated
with a 6% increased risk of AD over a mean follow-up of
5.9 years (n=4401) (see table 2 and ﬁgure 2).
As in all-cause dementia analyses, pooled risk estimates
for AD based on categorical depression thresholds
across 10 studies21 25 27 34 36 45–47 were higher for more
stringent clinical criteria. A clinical diagnosis or a score
greater than 20/21 on the CES-D (or equivalent) in
individuals (n=7831) in a pooled sample with a mean
age of 75.8 years (SD∼5) was associated with a 97%
increased risk of AD over a mean follow-up of 6.3 years.
Sensitivity analyses without the study by Fuhrer et al
which used the equivalent validated French thresholds
yielded a HR of 2.43 (95% CI 1.42 to 4.16). When a
cut-off of 1627 31 34 38 39 48 on the CES-D was used a 58%
increased risk was observed.
Depression and VaD risk
Very few studies provided risk estimates for VaD.
Consequently, although pooled estimates were com-
puted to provide approximate metrics to compare with
risk estimates for other dementia types, they should be
considered with caution. Only two studies29 49 (n=3187;
37 VaD cases) reported on continuous measures of
depressive symptomatology and produced a pooled risk
estimate of 1.06 (95%CI 0.92 to 1.21). Three
studies18 34 39 (n=13 331, 113+VaD cases) reported on
categorical depression thresholds that were most consist-
ent with a CES-D threshold of 16 and produced a
pooled risk estimate of 2.20 (95% CI 0.87 to 5.59).
Sensitivity analyses
For most analyses heterogeneity was low to moderate but
was substantial for CES-D subanalyses using a threshold
of 20. Inﬂuence of single studies was investigated with
leave-one-out analyses (see online supplementary appen-
dix SA1). In most part, they revealed no particularly
inﬂuential study which could be considered outliers with
some notable exceptions. The female cohort of Fuhrer
et al21 was found to be very inﬂuential and excluding it
from the analyses for any major depression diagnosis
with dementia as outcome (HR 2.29, 95% CI 1.81 to
2.88), for CES-D >20 with dementia as outcome (HR
2.56, 95% CI 1.71 to 3.84), and for CES-D >20 with AD
as outcome (HR 2.79, 95% CI 1.79 to 4.33) produced
notable but not signiﬁcantly different estimates.
Publication bias
Publication bias was formally investigated by two
methods. The fail-safe methods computes the number
of studies with null ﬁndings that would be needed to
reduce the signiﬁcance level to α=0.05. For most ana-
lyses a large number (n=43–142) of null studies would
need to be added to achieve an α level of 0.05 which
suggest overall robustness to bias. Exceptions were ana-
lyses using a threshold on the CES-D of ≥20 which had a
fail-safe estimate of 16 studies indicating a possible publi-
cation bias in these subanalyses. The second method
used to assess publication bias was the trim-and-ﬁll
method which estimates the number of missing studies
based on funnel plot asymmetry. The number of missing
studies ranged from 0 to 4 representing overall about
30% (range 20–50%) of the studies included in the ana-
lyses. These results suggest that some publication bias is
likely to be present and that actual effect sizes could be
smaller than those reported.
Meta-regression
Inﬂuence of study quality, proportion of females, length
of follow-up, and sample mean age, on pooled estimates
was investigated by meta-regression on the larger analysis
groups which estimated risk of all-cause dementia and
AD using all compatible continuous or categorical
depression measures. Some of the factors considered sig-
niﬁcantly predicted the unexplained variance in risk esti-
mates but only in analyses including continuous
measures of depression. First, when estimating the risk
of all-cause dementia while considering all continuous
measures of depression symptomatology, drop-out rate,
female proportion, mean age and study quality
accounted for 46% of unexplained variance. Studies
with higher drop-out rates (β −0.2263, SE 0.0921,
p=0.0140), a higher proportion of females (β −0.0077,
SE 0.0021, p=0.0003), lower mean age (β 0.0115, SE
0.0039, p=0.0031), and of higher quality (β −0.0873, SE
0.0370, p=0.0182) reported on average slightly lower risk
estimates. Second, when estimating the risk of AD while
considering all continuous measures of depression symp-
tomatology, female proportion and age accounted for
5% of unexplained variance. Studies with a higher pro-
portion of females (β −0.0122, SE 0.0052, p=0.0020) and
of lower mean age (β 0.0283, SE 0.0101, p=0.0052)
reported on average slightly lower risk estimates.
Incompatible studies
Apart from studies which could not be pooled in speciﬁc
subanalyses because they did not report on a relevant
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threshold on a speciﬁc instrument or on a speciﬁc
outcome, and those which reported on the same out-
comes in a single cohort,50–55 only a single study56 was
not included in any of the analyses. This is because it
was based on medical records and used ICD-9 classiﬁca-
tion to assess depression and dementia status with the
possibility that particularly the latter might not reach the
level of accuracy provided by methodologies used in
other studies which relied on more reliable clinical cri-
teria. However, because this study was larger than any
other (n=13 535) it is important to note that the esti-
mates it produced (dementia: HR1.77, 95% CI 1.52 to
2.06; AD: HR 2.06, 95% CI 1.67 to 2.55; VaD: HR 3.51,
95% CI 2.44 to 5.05) were remarkably consistent with
the pooled estimates reported in table 1, although some-
what higher than estimates reported above for VaD but
not signiﬁcantly so.
DISCUSSION
The major contribution of this study was to produce
precise dementia risk estimates associated with the pres-
ence of clinically signiﬁcant late-life depression or
depression symptomatology and which can be related to
speciﬁc thresholds on validated instruments. These ﬁnd-
ings are important because evidence-based clinical prac-
tice mandates that clinical advice and decision-making
be based on objective measures of risk. Until now, this
evidence was not available for speciﬁc instruments at
speciﬁed thresholds.
Great care was taken to avoid the combination of
incompatible ﬁndings. As such we were not only able to
conﬁrm that depression is associated with increased risk
of dementia but also to provide summary estimates
showing that this association is very similar for all-cause
dementia and AD. Importantly detailed analyses at spe-
ciﬁc cut-offs further conﬁrmed this pattern of associ-
ation. Of particular relevance to clinicians and
researchers, separate analyses of studies using a cut-off
most consistent with major depression and previously
validated against clinical criteria (CED-D>20)57 demon-
strated somewhat higher risk estimates (dementia HR
1.83 (trend) and AD HR 1.97) than those using a more
lenient cut-off (CES-D>16; dementia HR 1.58 (trend)
and AD HR 1.69). Together these ﬁndings suggest that
clinical depression is likely associated with an approxi-
mately 80–100% increased risk of dementia and AD.
However, milder presentation is still associated with an
approximately 60–70% increased risk of dementia and
AD. In this context it is noteworthy that Coopers et al58
found, when considering risk of transition from MCI to
dementia, that depression was associated with an
increased risk when focusing on population studies but
not when investigating clinical studies. The reason for
these ﬁndings remains to be elucidated. However, it is
possible that depression is most predictive of dementia
risk in the early, preclinical stages of the disease and
that in individuals involved in clinical studies who are
likely to be in more advanced stages of the disease,
depression is a less sensitive predictor.
Analyses of continuous measures with a similar range
(CES-D, HAM and SCL-90) or from the CES-D alone
also suggest depression may be associated with dementia
in a dose-dependent manner and possibly starting in the
subclinical range. Indeed, every one point increase on
these measures was associated with a 5–6% increased
risk of AD or dementia. The available data do not allow
us to investigate whether the demonstrated association is
driven by a stronger dose-dependent effect within the
clinical population or whether a smaller effect is at play
across the whole subclinical and clinical ranges. This
question should be addressed in future research as it
will lead to more reliable risk estimates and will help
clarify the extent to which those with subsyndromal
symptomatology are at risk.
Too few studies were available to produce reliable risk
estimates for VaD. However, despite this major limita-
tion, summary HRs for VaD were very consistent with
those produced for all-cause dementia and AD, and did
not signiﬁcantly differ (as demonstrated by the predom-
inantly overlapping CIs). Together these ﬁndings
suggest that the risk associated with depression does not
differ for the main types of dementia considered here.
Interestingly, meta-regression analyses showed that
higher drop-out rate, larger female proportion, younger
mean age and higher study quality ratings were asso-
ciated with lower dementia and AD risk estimates but
only when continuous depression measures were consid-
ered. These ﬁndings further emphasise the need for
very robust methodology in epidemiological research
based on designs that minimise drop-out, do not cover
excessively large age ranges (or stratify by age groups),
include similar proportions of males and females (or
stratify by sex), and that adhere and report high scien-
tiﬁc quality practices. It is also particularly notable that
according to our meta-regression analysis late-life depres-
sion in women appeared to be associated with a slightly
lower risk.
An incompletely resolved question is whether depres-
sion is a risk factor for dementia or whether it is an
early biomarker which indicates the development of
depressive symptomatology in the prodromal stages of
the disease. Indeed, while all studies included in the
present investigation excluded individuals presenting
with dementia at baseline, at least in those studies with
short follow-ups it could be argued that participants
might have already have developed mild cognitive
impairment and/or substantial cerebral pathology.
While this may be in part the case it is also unlikely that
depression is only a symptom of dementia and not a risk
for it. This is because even studies with long follow-ups
(eg, more than 20 years in Dotson et al37) have found a
signiﬁcant risk of dementia associated with depression
but perhaps even more convincing is the profuse evi-
dence demonstrating links between the development of
depression and increased neuroinﬂammation, oxidative
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stress, white matter lesions and cerebral atrophy which
are already detectable in younger cohorts (see ref. 59 for
a review and discussion).
Major strengths of this study were that it used a robust
methodology which included a very broad search of the
literature using clearly deﬁned search terms and strin-
gent inclusion and exclusion criteria. Particular care was
taken to assess study characteristics so only studies which
used compatible exposure and outcome measures would
be combined. Detailed subanalyses were conducted to
provide estimates for speciﬁc tools at speciﬁc thresholds.
Moreover, study quality, publication bias, and inﬂuence
of relevant factors were formally investigated by
meta-regression. However, the study was limited by the
relatively small number of articles with relevant data
published in this domain and particularly so for VaD.
Estimated HRs had relatively wide CIs which suggest that
further research is required to produce even more
precise estimates. The fact that the CES-D was the only
instrument that could be analysed separately was also a
limitation. Another limitation stems from the fact that
different studies did not control for exactly the same
covariates which may have somewhat biased estimates.
In conclusion, when considering speciﬁc screening
instruments at speciﬁed threshold, late-life depression
and depressive symptomatology are consistently asso-
ciated with an increased risk of dementia and AD. The
CES-D is the only psychometric instrument for which
speciﬁc risk estimates could be computed at known vali-
dated thresholds (16 and 20). More research needs to
be conducted to determine the extent to which depres-
sive symptomatology in the subclinical range is asso-
ciated with increased dementia risk. While this study
could only demonstrate associations and not causal
links, available evidence support the view that depressive
symptomatology is associated with pathological mechan-
isms associated with neurodegeneration.59 Therefore,
preventative approaches to reduce the prevalence and
virulence of depressive illness need to be further devel-
oped as, in addition to personal costs, it will be asso-
ciated with exponential social and economic costs in our
ageing population.
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